CELL DEATH AND DIFFERENTIATION-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2020-08-29 wisper speed

请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor

108 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-10-13 雨念来自浙江省

求助：推荐receiving editor 是从哪里找呀

22 0

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-10-13 雨念来自浙江省

推荐编辑要去哪里找呀

14 0

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-10-11 ms7000001872542172 来自江苏省

还没投

25 0

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-09-09 小懒emma 来自河南省

请问article 的字数超过8000可以吗

33 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-06-01 尊严

偏重的研究方向：分子生物学
经验分享：能比的上NC和Sci Adv不？

46 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-06-20 ms7000000166750616 来自山东省

请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了

40 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2021-04-29 里开朗琪罗

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：分子生物学研究 ; 发病机制
经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。

130 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-08-13 124a8810m95(暂无昵称) 来自重庆

被直接拒了，修改后可以重投吗？

43 0

[GetPortalCommentsPageByObjectIdResponse(id=880530, encodeId=f06b880530f4, content=请问receiving editor在哪里选择啊？我收到邮件让我推荐receiving editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=108, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210205/05b5037b86db4c98a206f2987b4d2b0a/90631ca66a734b018e412f1891933dce.jpg, createdBy=6a6f1855273, createdName=wisper speed, createdTime=Sat Aug 29 01:20:57 CST 2020, time=2020-08-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2162627, encodeId=fc4c216262e20, content=求助：推荐receiving editor 是从哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 18:13:02 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162654, encodeId=2f872162654d2, content=推荐编辑要去哪里找呀, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=14, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a0a22184874, createdName=雨念, createdTime=Fri Oct 13 21:52:45 CST 2023, time=2023-10-13, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=2162223, encodeId=831e216222304, content=还没投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=10c45584861, createdName=ms7000001872542172, createdTime=Wed Oct 11 18:42:27 CST 2023, time=2023-10-11, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2156927, encodeId=fe79215692eed, content=请问article 的字数超过8000可以吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=33, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201213/0c5ac7effe254ae4bce0fa2cc2887867/6649319072f04f49b9aaca73a211cec5.jpg, createdBy=9aac2516251, createdName=小懒emma, createdTime=Sat Sep 09 22:59:27 CST 2023, time=2023-09-09, status=1, ipAttribution=河南省), GetPortalCommentsPageByObjectIdResponse(id=2140353, encodeId=b699214035354, content=偏重的研究方向：分子生物学 经验分享：能比的上NC和Sci Adv不？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=46, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200529/ba3f7315b20948fe825bf4dddc7209da/51f5ca756fdb4c499362b29a2af5657b.jpg, createdBy=cabf5294282, createdName=尊严, createdTime=Thu Jun 01 17:31:11 CST 2023, time=2023-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2143786, encodeId=bebc2143e869a, content=请问这个期刊现在二审平均多久呀？修回之后没有邮件提示投稿，状态到现在一直是under consideration，现在已经等了一个多月了，我看了一下实验室之前投稿这个杂志二审平均一两周就接收了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=40, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9886482099, createdName=ms7000000166750616, createdTime=Tue Jun 20 01:02:20 CST 2023, time=2023-06-20, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=961439, encodeId=b08896143900, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：分子生物学研究 ; 发病机制 经验分享：我也来分享下自己的经验吧。2020年10月19日投稿，12月10收到返修意见。一般给4个月的修改时间，两个审稿人每个人提出5到10个不等的意见。21年3月24日送二审，4月14日原则上接收，填一个信息表，4月16正式接收。自己在杂志上基本上只能看到under consideration和accepted两种状态，只有通讯作者才会收到各种信息。硕士3年，博士6年，终于毕业了。本人还有一篇参与的文章在这个杂志到返修阶段，对这个杂志还是有点了解的。祝大家文章接收，有问题可以及时交流。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1cb35481290, createdName=里开朗琪罗, createdTime=Thu Apr 29 08:33:25 CST 2021, time=2021-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2152588, encodeId=17b221525887f, content=被直接拒了，修改后可以重投吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/54ae98c06fadb8aed43498766caa8965/ed2d418443fb9273ce63b78308e197be.jpg, createdBy=217c2504826, createdName=124a8810m95(暂无昵称), createdTime=Sun Aug 13 21:18:27 CST 2023, time=2023-08-13, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2137433, encodeId=5f48213e4331e, content=审稿速度:3.0 | 投稿命中率:50.0 偏重的研究方向：分子生物学;DNA损伤;肿瘤 经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=41, replyNumber=13, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu May 18 11:23:23 CST 2023, time=2023-05-18, status=1, ipAttribution=江苏省)]

2023-05-18 121ec805m86(暂无昵称) 来自江苏省

审稿速度:3.0 | 投稿命中率:50.0
偏重的研究方向：分子生物学;DNA损伤;肿瘤
经验分享：2月份投稿，初审两个半月，2023-5-2修回。两个审稿人9条意见，很友好没有让补实验，编辑要求5-28之前返回。5-18返回，等消息。

41 13

展开13条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务